Human Enhancement Drugs Network (HEDN) Symposium

Theme: Human Enhancement Drugs and New Research Directions

Led by Dr Katinka van de Ven & Dr Kyle Mulrooney

When: Tue the 11th of Feb 2020 (10.00am-4.30pm)

Where: Paramatta campus, UNE, Sydney

The aim of the symposium is to bring together a broad spectrum of scholarly insights and research expertise from various disciplines, such as public health, epidemiology, neuroethics, sport science, criminology and sociology, to examine key (inter)national issues in the field of HEDs.

The symposium will facilitate debates on our understanding of the cultural and societal contexts of HED use and supply, as well as the critical analysis of the consequences of (drug) policy implementation. These debates will be used to inform and develop contributions to a themed collection for the International Journal of Drug Policy (IJDP) (Q1) entitled ‘Human enhancement drugs: emerging issues and responses’. More information HERE.

Please submit abstracts of no more than 350 words to Dr Katinka van de Ven ([email protected]) by:

15 December 2019

In preparation for the symposium, full working papers based on the accepted abstracts selected will need to be submitted to Dr van de Ven by the 29th of Jan 2020.

While the symposium will take place in Sydney, Australia, international applicants are encouraged to participate via video-link.

If you also would like your submission for the symposium to also be considered for the themed collection in IJDP copy Dr Vivian Hope ([email protected]) into the email, noting that you would like to be considered for the special issue.

Travel bursaries of $250 are available and will be awarded to 7 applicants. Please email Dr van de Ven by the 27th of November if interested in this.

Submissions related to the following themes would be of particular interest:

  • emerging patterns of human enhancement drug use and supply, the use of new types of enhancement drugs, and emergent harms;
  • the relationship between use of enhancement and psychoactive drugs;
  • motivations and drivers for enhancement drug use, particularly use to enhance intellectual, creative and social functioning, or to improve appearance or attractiveness to others;
  • the diversity of populations using enhancement drugs including their use amongst marginalised and minority groups;
  • the boundary between use for therapy, repair and enhancement;
  • the formulation and impact of policy, regulations and laws related to drugs and drug use; and
  • factors impacting on, and the development and implementation of, interventions and other responses to human enhancement drug use to prevent and reduce harm.

Please contact Dr van de Ven for more information on the symposium and travel bursaries ([email protected]).